/
Oncology
Chronic Lymphocytic Leukemia
78
Pipeline Programs↗
165
Active Trials↗
81
Companies Involved↗
Chronic Lymphocytic Leukemia is a moderately active landscape with 78 programs across 81 companies. The most active players are BeOne Medicines, Lomond Therapeutics Holdings, Inc., Guangzhou Lupeng Pharmaceutical Company LTD.. 16 programs are in Phase 3.
Intelligence
Pipeline Metrics
Competitive Density
Pipeline Velocity
Mech. Concentration
Completion Rate
Attrition Rate
Competition
Competitive Landscape
Bubble size = clinical trials
Approved
Phase 3
Phase 2
Phase 1
Preclinical
Key Players
Top Companies Companies ranked by the number of pipeline programs they run for this disease.
Pipeline
Programs by Phase
Preclinical13
Phase 110
Phase 239
Phase 316
Approved
No programs
Analysis
Modality Breakdown
70%
Small molecule
46 of 66 classified programs — the dominant modality here.
Small molecule leads; the ring shows all 66 classified programs, each share of the total. Modality classified for 94% of 78 pipeline programs.
Analysis
Trial Status
693
clinical trials
Completed357 · 52%
Terminated100 · 14%
Recruiting75 · 11%
Active, not recruiting73 · 11%
Withdrawn39 · 6%
Unknown status28 · 4%
Other21 · 3%
Clinical Trials
Trial Activity
693 trials
Page 1 of 47
Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)